|
KR20210032014A
(ko)
|
2012-04-11 |
2021-03-23 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
CN103965361B
(zh)
*
|
2013-02-06 |
2018-10-30 |
上海细胞治疗工程技术研究中心集团有限公司 |
一种t细胞信号的嵌合分子转换器及其用途
|
|
EP3623380B1
(en)
|
2013-03-15 |
2025-10-22 |
Novartis AG |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
CN104072616A
(zh)
*
|
2013-03-29 |
2014-10-01 |
上海中信国健药业股份有限公司 |
一种嵌合受体及其制备方法和用途
|
|
US10358494B2
(en)
|
2013-05-03 |
2019-07-23 |
Ohio State Innovation Foundation |
CS1-specific chimeric antigen receptor engineered immune effector cells
|
|
EP2994530A4
(en)
|
2013-05-10 |
2016-11-16 |
Whitehead Biomedical Inst |
PROTEIN MODIFYING LIVING CELLS USING SORTASE
|
|
CN105722522B
(zh)
|
2013-08-30 |
2021-10-19 |
得克萨斯大学体系董事会 |
用于肿瘤疗法的犬尿氨酸耗竭酶的施用
|
|
ES2845924T3
(es)
*
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
DK3071222T3
(da)
*
|
2013-11-21 |
2020-11-16 |
Ucl Business Ltd |
Celle
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
ES2767423T3
(es)
*
|
2014-01-13 |
2020-06-17 |
Hope City |
Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
|
|
AU2015239683B2
(en)
*
|
2014-04-01 |
2019-08-22 |
Astellas Pharma Inc. |
Claudin-6-Specific immunoreceptors and T cell epitopes
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
MX2016013149A
(es)
*
|
2014-04-10 |
2017-04-27 |
Seattle Children's Hospital (Dba Seattle Children's Res Institute) |
Produccion de celulas t modificadas, mediante transposon bella durmiente, acoplada con seleccion por metotrexato.
|
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
|
US10550197B2
(en)
|
2014-06-18 |
2020-02-04 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
CAR-expressing NK-92 cells as cell therapeutic agents
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
AU2015308818B2
(en)
*
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
|
US9975959B2
(en)
|
2014-08-29 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
|
WO2016061286A2
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
|
WO2016115445A1
(en)
*
|
2015-01-16 |
2016-07-21 |
The Johns Hopkins University |
Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
|
|
EP3250605A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
|
|
GB201501936D0
(en)
*
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
|
US20170151281A1
(en)
*
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
CN107530424A
(zh)
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
US20180298098A1
(en)
*
|
2015-02-26 |
2018-10-18 |
Var2 Pharmaceutical Aps |
Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
|
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
|
HK1250918A1
(zh)
|
2015-04-06 |
2019-01-18 |
Cytoimmune Therapeutics, Inc. |
用於胶质母细胞瘤的egfr导向的car疗法
|
|
EP3283113A4
(en)
*
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
HK1252854A1
(zh)
*
|
2015-04-23 |
2019-06-06 |
哈马洛吉克斯有限公司 |
κ骨髓瘤抗原嵌合性抗原受体和其用途
|
|
EP4272757A3
(en)
|
2015-06-10 |
2023-12-27 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
GB2592821B
(en)
*
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
AU2016301196B2
(en)
*
|
2015-08-06 |
2022-09-08 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
|
CN108174604B
(zh)
|
2015-08-07 |
2023-06-23 |
西雅图儿童医院（Dba西雅图儿童研究所） |
用于实体瘤靶向的双特异性car t细胞
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
MA44907A
(fr)
*
|
2015-09-11 |
2018-07-18 |
Agenus Inc |
Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
|
|
GB201518136D0
(en)
*
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
US11400145B2
(en)
*
|
2015-11-27 |
2022-08-02 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
US11542486B2
(en)
|
2016-03-02 |
2023-01-03 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
CN117903307A
(zh)
|
2016-04-01 |
2024-04-19 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
AU2017240788B2
(en)
|
2016-04-01 |
2020-04-09 |
Amgen Inc. |
Chimeric receptors and methods of use thereof
|
|
PE20190173A1
(es)
|
2016-04-01 |
2019-02-01 |
Kite Pharma Inc |
Receptores de antigenos quimericos y celulas t y metodos de uso
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
SG11201809041TA
(en)
*
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
KR20240148936A
(ko)
|
2016-05-13 |
2024-10-11 |
바이오아트라, 인코퍼레이티드 |
항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
|
US20190262397A1
(en)
|
2016-07-26 |
2019-08-29 |
Tessa Therapeutics Pte. Ltd. |
Chimeric antigen receptor
|
|
CA3036713A1
(en)
|
2016-09-29 |
2018-04-05 |
Nantkwest, Inc. |
Hla class i-deficient nk-92 cells with decreased immunogenicity
|
|
SG11201903282TA
(en)
|
2016-10-13 |
2019-05-30 |
Juno Therapeutics Inc |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
KR20230172612A
(ko)
|
2016-10-19 |
2023-12-22 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
|
MX2019007404A
(es)
|
2016-12-23 |
2019-09-27 |
Macrogenics Inc |
Moleculas de union a adam9 y metodos de uso de las mismas.
|
|
CN110168078B
(zh)
|
2017-01-06 |
2024-05-14 |
免疫生物公司 |
具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
US11311609B2
(en)
|
2017-02-08 |
2022-04-26 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
KR20190142775A
(ko)
|
2017-04-19 |
2019-12-27 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
조작된 항원 수용체를 발현하는 면역 세포
|
|
CN111065407A
(zh)
*
|
2017-06-16 |
2020-04-24 |
普罗特利卡公司 |
纤连蛋白结合结构域嵌合抗原受体及其使用方法
|
|
WO2019002633A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
|
|
IL316522A
(en)
*
|
2017-10-18 |
2024-12-01 |
Precigen Inc |
Polypeptide compositions containing spacers
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
AU2018362014A1
(en)
|
2017-11-03 |
2020-05-28 |
Sorrento Therapeutics, Inc. |
CD38-directed chimeric antigen receptor constructs
|
|
WO2019099707A1
(en)
*
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
BR112020014913A2
(pt)
|
2018-01-22 |
2020-12-08 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Métodos para uso de células t car
|
|
US12162920B2
(en)
*
|
2018-01-26 |
2024-12-10 |
Chongqing Precision Biotech Company Limited |
Hinge area and use of same in constructing car skeleton
|
|
DE112019000608B4
(de)
|
2018-01-31 |
2021-05-06 |
Nantkwest, Inc. |
Verwendung von 5 % humanalbumin in wasch- und erntemedien
|
|
BR112020015884A2
(pt)
|
2018-02-06 |
2020-12-08 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
EP3755366A4
(en)
|
2018-02-23 |
2021-12-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CN112119157B
(zh)
|
2018-03-06 |
2025-01-14 |
宾夕法尼亚大学董事会 |
前列腺特异性膜抗原car及其使用方法
|
|
EP3743446A1
(en)
|
2018-03-12 |
2020-12-02 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
WO2019204269A1
(en)
|
2018-04-16 |
2019-10-24 |
Board Of Regents, The University Of Texas System |
Human kynureninase enzymes and uses thereof
|
|
EP3784696A1
(en)
|
2018-04-23 |
2021-03-03 |
Baylor College Of Medicine |
Chimeric hla accessory receptor
|
|
CN112166193A
(zh)
*
|
2018-05-21 |
2021-01-01 |
生物权威（英国）有限公司 |
具有经修饰的接头结构域的嵌合抗原受体及其用途
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
KR102587512B1
(ko)
|
2018-05-22 |
2023-10-11 |
이뮤너티바이오, 인크. |
폴록사머를 사용한 nk-92 세포 성장의 최적화
|
|
CN112166183A
(zh)
|
2018-05-22 |
2021-01-01 |
南克维斯特公司 |
用于生长nk92细胞的基础培养基
|
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
WO2020014245A1
(en)
|
2018-07-10 |
2020-01-16 |
Nantkwest, Inc. |
Cryopreservation
|
|
JP7190022B2
(ja)
|
2018-07-10 |
2022-12-14 |
イミュニティーバイオ インコーポレイテッド |
臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
|
|
WO2020028654A1
(en)
|
2018-08-01 |
2020-02-06 |
Nantkwest, Inc. |
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
CN119752898A
(zh)
|
2018-08-01 |
2025-04-04 |
南克维斯特公司 |
用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
|
|
AU2018434924A1
(en)
|
2018-08-01 |
2021-01-28 |
Immunitybio, Inc. |
Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
|
|
EP3743513A4
(en)
|
2018-11-06 |
2021-11-24 |
Nantkwest, Inc. |
NK-92 CELLS MODIFIED BY A CHEMICAL ANTIGENIC RECEPTOR
|
|
US12109238B2
(en)
|
2018-11-06 |
2024-10-08 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
CN113164521A
(zh)
|
2018-11-26 |
2021-07-23 |
免疫生物公司 |
具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
|
|
CN118546960A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
US20220184128A1
(en)
*
|
2019-03-28 |
2022-06-16 |
Korea Research Institute Of Bioscience And Biotechnology |
Method for producing car gene-introduced nk cells and use thereof
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
MA56036A
(fr)
|
2019-05-27 |
2022-04-06 |
Immatics Us Inc |
Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
|
|
IL314722A
(en)
|
2019-08-01 |
2024-10-01 |
Immunitybio Inc |
Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
|
|
KR102287180B1
(ko)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
WO2021066751A1
(en)
*
|
2019-10-02 |
2021-04-08 |
Aslan Pharmaceuticals Pte. Ltd. |
Antigen specific binding domains and antibody molecules
|
|
AU2019468311B2
(en)
*
|
2019-11-26 |
2023-05-18 |
Immunitybio, Inc. |
Primary NK CAR constructs and methods
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
CN115397974A
(zh)
|
2020-01-23 |
2022-11-25 |
儿童医疗中心有限公司 |
由人类多能干细胞进行无基质t细胞分化
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
WO2021162394A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
충북대학교 산학협력단 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
JP2023522038A
(ja)
*
|
2020-04-17 |
2023-05-26 |
２セブンティ バイオ インコーポレイテッド |
修飾ｃｃｒポリペプチド及びその使用
|
|
WO2021217113A1
(en)
*
|
2020-04-25 |
2021-10-28 |
East Carolina University |
Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein
|
|
WO2021221927A1
(en)
|
2020-04-27 |
2021-11-04 |
Parsons Corporation |
Narrowband iq signal obfuscation
|
|
AU2021283714A1
(en)
|
2020-06-05 |
2023-01-19 |
Tessa Therapeutics Ltd. |
Treatment of CD30-positive cancer
|
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
|
WO2022098756A1
(en)
*
|
2020-11-03 |
2022-05-12 |
WUGEN, Inc. |
Chimeric antigen receptor cell therapy
|
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス，インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
|
WO2022109611A1
(en)
|
2020-11-20 |
2022-05-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
|
KR20220082775A
(ko)
|
2020-12-10 |
2022-06-17 |
주식회사 유틸렉스 |
항-pd-1 항체 및 이의 용도
|
|
CN114716548B
(zh)
|
2021-01-05 |
2024-11-05 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
|
WO2022182891A1
(en)
|
2021-02-25 |
2022-09-01 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
EP4308133A4
(en)
|
2021-03-17 |
2025-01-22 |
Myeloid Therapeutics, Inc. |
MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20240190935A1
(en)
*
|
2021-04-26 |
2024-06-13 |
East Carolina University |
Compositions and methods of treating pathogenic infections by using fusion proteins
|
|
WO2022232797A2
(en)
|
2021-04-27 |
2022-11-03 |
Baylor College Of Medicine |
Virus-specific immune cells expressing chimeric antigen receptors
|
|
KR20240037192A
(ko)
|
2021-05-11 |
2024-03-21 |
마이얼로이드 테라퓨틱스, 인크. |
게놈 통합을 위한 방법 및 조성물
|
|
WO2023072953A1
(en)
|
2021-10-26 |
2023-05-04 |
Tessa Therapeutics Ltd. |
Cell lines for producing a retroviral vector encoding a car
|
|
TW202328438A
(zh)
|
2021-12-08 |
2023-07-16 |
新加坡商泰莎治療有限公司 |
淋巴瘤之治療
|
|
JP2025513890A
(ja)
|
2022-04-13 |
2025-04-30 |
ティクヴァ アロセル プライベート リミテッド |
治療用ｔ細胞製品
|
|
JP2025519556A
(ja)
|
2022-06-10 |
2025-06-26 |
リサーチ ディベロップメント ファウンデーション |
操作されたＦｃＲＩＩｂ選択的ＩｇＧ１ Ｆｃバリアントおよびその使用
|
|
IL318546A
(en)
|
2022-07-26 |
2025-03-01 |
Aimed Bio Inc |
Anti-ROR1 antibody and its uses
|